Helixgate

Helixgate

Uncategorized

Revolution pancreatic cancer drug nearly doubles survival in key trial

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor. 

Read More

Published

on

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor. 

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Could biotech layoffs push life sciences talent to go global?

Could biotech layoffs push life sciences talent to go global?

Published

on

Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.​ ​Read More

Continue Reading

Uncategorized

5 biopharma M&A deals where the workforce was the prize

Published

on

Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.

Continue Reading

Uncategorized

Deep dive: Checking in with the FDA

Published

on

BioSpace looks back at 2025 and where the FDA is going in 2026.

Continue Reading
Advertisement

Trending